Clinical Trial Update: A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema

View source ↗

Summary

Takeda-sponsored pediatric trial evaluating icatibant for hereditary angioedema has completed. The trial identifier is NCT05509569.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• ICATIBANT (icatibant)

Snippet

Sponsor: Takeda | Conditions: Hereditary Angioedema (HAE) | Status: COMPLETED